The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...

—A large data analysis found a significantly heightened relative risk of optic neuritis in NMOSD, MOGAD, and other inflammatory diseases, supporting prompt evaluation of visual complaints in these ...

Vision – To be the world's leading and most trusted provider of information and services that will make a real difference in clinical practice and improve outcomes for patients. Mission – To lead the ...

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 ...

"Patients with anti-AQP4-Ab may basically need long-term relapse prevention, because they surely experience much higher relapse activity, with much worse neurological disturbance…In MOGAD patients, ...

Oculis (OCS) stock jumps as the FDA grants Breakthrough Therapy designation for its eye disease drug Privosegtor targeted at ...